Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEN Compugen	$1.64 -0.6%	$1.49	$1.13 ▼ $2.66	$147.24M	2.54	371,516 shs	109,814 shs
EDIT Editas Medicine	$2.22 -5.5%	$1.67	$0.91 ▼ $6.05	$196.73M	2.1	2.59 million shs	3.06 million shs
NMRA Neumora Therapeutics	$0.79 +0.7%	$0.75	$0.61 ▼ $17.19	$126.16M	2.73	1.54 million shs	874,997 shs
PSTI Pluristem Therapeutics		$1.24	$0.95 ▼ $3.45	$32.35M	1.91	715,259 shs	2,128 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEN Compugen	-0.61%	0.00%	+17.99%	+4.46%	-11.83%
EDIT Editas Medicine	-5.53%	+12.69%	+48.00%	+69.47%	-55.95%
NMRA Neumora Therapeutics	+0.73%	-6.96%	+4.12%	-30.47%	-91.41%
PSTI Pluristem Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEN Compugen	1.4473 of 5 stars	3.5	3.0	0.0	0.0	1.1	0.0	0.0
EDIT Editas Medicine	3.806 of 5 stars	3.2	2.0	0.0	4.2	1.4	2.5	0.6
NMRA Neumora Therapeutics	1.518 of 5 stars	3.1	0.0	0.0	0.0	0.6	2.5	1.3
PSTI Pluristem Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEN Compugen	3.00	Buy	$4.00	143.90% Upside
EDIT Editas Medicine	2.31	Hold	$4.70	111.71% Upside
NMRA Neumora Therapeutics	2.22	Hold	$9.29	1,081.84% Upside
PSTI Pluristem Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PSTI, CGEN, EDIT, and NMRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $4.00
5/13/2025	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/29/2025	EDIT Editas Medicine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00
4/10/2025	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/2/2025	NMRA Neumora Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Underperform	$7.00 ➝ $1.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEN Compugen	$27.86M	5.25	N/A	N/A	$0.62 per share	2.65
EDIT Editas Medicine	$32.31M	5.75	N/A	N/A	$1.63 per share	1.36
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
PSTI Pluristem Therapeutics	$20K	0.00	N/A	N/A	$1.80 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEN Compugen	-$14.23M	-$0.16	N/A	N/A	N/A	-51.27%	-24.51%	-12.19%	8/5/2025 (Estimated)
EDIT Editas Medicine	-$237.09M	-$3.04	N/A	N/A	N/A	-701.06%	-139.24%	-63.87%	8/6/2025 (Estimated)
NMRA Neumora Therapeutics	-$243.79M	-$1.61	N/A	N/A	N/A	N/A	-84.79%	-77.57%	8/5/2025 (Estimated)
PSTI Pluristem Therapeutics	-$49.87M	-$1.47	N/A	N/A	N/A	N/A	-100.63%	-55.46%	N/A

Latest PSTI, CGEN, EDIT, and NMRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/19/2025	Q1 2025	CGEN Compugen	-$0.06	-$0.08	-$0.02	-$0.08	$3.70 million	$2.28 million
5/12/2025	Q1 2025	EDIT Editas Medicine	-$0.51	-$0.43	+$0.08	-$0.92	$0.79 million	$4.66 million
5/12/2025	Q1 2025	NMRA Neumora Therapeutics	-$0.40	-$0.42	-$0.02	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
PSTI Pluristem Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEN Compugen	N/A	5.09	5.09
EDIT Editas Medicine	N/A	3.08	3.08
NMRA Neumora Therapeutics	N/A	8.98	8.98
PSTI Pluristem Therapeutics	0.57	8.22	8.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEN Compugen	12.22%
EDIT Editas Medicine	71.90%
NMRA Neumora Therapeutics	47.65%
PSTI Pluristem Therapeutics	16.94%

Insider Ownership

Company	Insider Ownership
CGEN Compugen	9.50%
EDIT Editas Medicine	2.10%
NMRA Neumora Therapeutics	26.80%
PSTI Pluristem Therapeutics	5.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEN Compugen	70	89.24 million	80.76 million	Optionable
EDIT Editas Medicine	230	83.71 million	81.96 million	Optionable
NMRA Neumora Therapeutics	108	161.75 million	118.40 million	Optionable
PSTI Pluristem Therapeutics	153	32.35 million	30.60 million	Optionable

PSTI, CGEN, EDIT, and NMRA Headlines

Recent News About These Companies

Editorial Board — Medscape Oncology

September 2, 2024 | medscape.com

NBRVF Nabriva Therapeutics plc

August 18, 2023 | seekingalpha.com

Pluri CEO Issues Shareholder Update

July 25, 2022 | finance.yahoo.com

Pluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries

July 25, 2022 | benzinga.com

Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries

July 25, 2022 | finance.yahoo.com

Pluristem (PSTI) Phase III Study Misses Goal, Stock Down

July 14, 2022 | finance.yahoo.com

Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery

July 13, 2022 | finance.yahoo.com

Pluristem's Phase 3 Study Of PLX-PAD To Treat Muscle Injury Does Not Meet Primary Goal

July 13, 2022 | markets.businessinsider.com

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

July 13, 2022 | finance.yahoo.com

Pluristem: Fiscal Q3 Earnings Snapshot

May 10, 2022 | apnews.com

Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership

March 28, 2022 | finance.yahoo.com

Pluristem PLX-R18 shows promise in blood cell recovery in cell transplant patients in trial

March 23, 2022 | seekingalpha.com

Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions

March 23, 2022 | finance.yahoo.com

Pluristem Therapeutics, Inc. Common Stock (PSTI)

March 21, 2022 | nasdaq.com

Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture

March 8, 2022 | finance.yahoo.com

Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform

February 24, 2022 | finance.yahoo.com

Pluristem: Fiscal Q2 Earnings Snapshot

February 8, 2022 | timesunion.com

What Are The Analysts’ Predictions For Pluristem Therapeutics Inc. (NASDAQ: PSTI)?

January 18, 2022 | stocksregister.com

Thinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?

January 12, 2022 | marketwatch.com

Pluristem Therapeutics Inc. (NASDAQ: PSTI) Is On The Rise

January 11, 2022 | stocksregister.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Alphabet Stock Lags—But Waymo May Be Its Hidden Driver
By Gabriel Osorio-Mazilli | May 25, 2025
View Alphabet Stock Lags—But Waymo May Be Its Hidden Driver

PSTI, CGEN, EDIT, and NMRA Company Descriptions

Compugen NASDAQ:CGEN

$1.64 -0.01 (-0.61%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.64 0.00 (-0.30%)

As of 06/20/2025 07:50 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Editas Medicine NASDAQ:EDIT

$2.22 -0.13 (-5.53%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.19 -0.03 (-1.13%)

As of 06/20/2025 07:55 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Neumora Therapeutics NASDAQ:NMRA

$0.79 +0.01 (+0.73%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$0.80 +0.01 (+1.82%)

As of 06/20/2025 06:58 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Pluristem Therapeutics NASDAQ:PSTI

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time